Reorganisation &Consolidation

RNS Number:7530M
Cytomyx Holdings PLC
25 June 2003


25th June 2003


Cytomyx Holdings consolidates Cytocell acquisition

Cytomyx Holdings Plc ("Cytomyx" or the "Company") announces that following the
acquisition of goodwill and assets from Cytocell Limited ("Cytocell") in March
2003, it is undertaking a consolidation of its operations into the Cambridge
site.


All operations at Banbury, formerly the premises of Cytocell, will move to the
main Cytomyx facility in Cambridge by August 2003. As part of the consolidation,
the company has announced nine redundancies across the two sites. The move will
streamline costs and facilitate an efficient integration of the businesses.


Chief Executive Mike Kerins commented "Cytomyx has acquired two exciting
businesses in the last nine months and we have also recently reported promising
progress in our interim results, taking us close to break-even. This
restructuring is a necessary step that will enable us to realise synergies and
substantial cost efficiencies for our overall operation, which has expanded
rapidly in the last year. The reduction in manpower costs and the inevitable
overhead savings associated with merging two sites into one will be of great
benefit to the Group.


Our aim is to continue our growth with a more efficiently integrated operation
on our Cambridge site, and to achieve profitability at the earliest possible
opportunity."


As part of the realignment, Dr. Nick Pay the Group's Commercial Director and
acting Managing Director of the Banbury site will step down from these roles and
revert to Non-Executive director with a continuing role for business
development. Specific managers with responsibility for commercial development
within the different business units have been appointed.




Contact:- Cytomyx

Karen Chandler-Smith
Tel: [phone]
Fax:[phone]

Cytomyx
6-7 Technopark
Cambridge
CB5 8PB
UK
email: [e-mail]
Web: www.cytomyx.com

Or

Andrew Marshall
Marshall Robinson Roe
Tel: [phone]




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCBBGDLXXDGGXU